Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
UBS–SEVERAL: investment, 201604 final closing of $471m UBS Oncology Impact Fund which will be advised by MPM Capital 2016-04-27
Evotec–Exscientia: cancer immunotherapy, 201604– collab r+d bi-specific small molecule immuno-oncology therapies co-owned + risk-shared 2016-04-26
Wilex–SEVERAL: investment, 201604 capital increase €4.13m with 2.25m new shares at €1.84/share whereof >50% to Dievini Hopp 2016-04-25
Aptuit–Welsh Carson Anderson & Stowe: investment, 201604 existent Aptuit LLC is portfolio company of WCAS 2016-04-21
Exquiron Biotech–Aptuit: investment, 201604 acquisition by Aptuit LLC 2016-04-21
F-Star–Hume Brophy: public relations, 201604 service existent by Hume Brophy London 2016-04-21
Enterome–BPCE: investment, 201604 financing round Series C totalling €14.5m incl co-lead + existing investor Seventure Partners 2016-04-20
Enterome–Lundbeck: investment, 201604 financing round Series C totalling €14.5m incl co-lead + existing investor Lundbeckfond Ventures 2016-04-20
Enterome–Nestlé: investment, 201604 financing round Series C totalling €14.5m incl new + co-investor Nestlé Health Science 2016-04-20
Enterome–SEVERAL: investment, 201604 financing round Series C €14.5m led by Seventure Partners + Lundbeckfond Ventures plus Nestlé Health et al 2016-04-20
Second Genome–Roche: investment, 201604 financing round Series B totalling $42.6m co-led by Pfizer Venture Investments + Roche Venture Fund 2016-04-20
Second Genome–SEVERAL: investment, 201604 financing round Series B $42.6m co-led by Pfizer Venture Investments + Roche Venture Fund 2016-04-20
Univ Lausanne–Saphetor: bioinformatics, 201604– supply CHUV to use Saphetor’s precision medicine platform for research + clinical applications 2016-04-20
G-Therapeutics–Gimv: investment, 201604 financing round Series A totalling €26m incl co-investor Gimv 2016-04-19
G-Therapeutics–Netherlands (govt): credit, 201604 deferred risk-bearing innovation loan €10m from RvO 2016-04-19
G-Therapeutics–SEVERAL: investment, 201604 financing round Series A €26m co-led by LSP + INKEF Capital + Gimv + Wellington Partnes 2016-04-19
HMNC–R-Biopharm: molecular companion diagnostics, 201604– collab €na developm PCR-based ABCB1 CDx for depression therapy 2016-04-19
Minapharm–Eucodis: ADC technology, 201604– license excl for C-LiNK (CTAT) technology to ProBioGen 2016-04-19
Pierre Fabre–Evotec: compound management, 201604–201103 supply service €na sample management for Pierre Fabre by Evotec Toulouse 2016-04-19
Hopp Group–Promethera: investment, 201604 acquisition of key assets of Cytonet in shares w Hopp family holding up to 13% of Promethera afterwards 2016-04-18
Promethera–Hopp Group: investment, 201604 Hopp family holding up to 13% of Promethera after sale of key assets of Cytonet to Promethera 2016-04-18
Crelux–WuXi PharmaTech: investment, 201604 acquisition of Crelux GmbH by WuXi AppTec 2016-04-15
Agena Bioscience–Horizon Discovery: reference standards, 201604– supply + distribution agreem for iPLEX standards for MassARRAY oncology assays 2016-04-14
GeNeuro–SEVERAL: investment, 201604 IPO €33m+€1k IPO with 2.54m+9.4k new shares at Euronext Paris 2016-04-14
Mirati–Qiagen: molecular companion diagnostics, 201604– collab developm + commercialisation of RNA-based CDx for glesatinib 2016-04-13
KWS Saat–HZPC: investment, 201604 acquisition €na of conventional seed potato business of KWS by Stet Holland BV 2016-04-11
STAT-Diagnostica–Boehringer: investment, 201604 financing round Series C totalling €25m incl returning co-investor BIVF 2016-04-11
STAT-Diagnostica–Gilde Investment: investment, 201604 financing round Series C totalling €25m incl led + new investor Gilde Healthcare 2016-04-11
STAT-Diagnostica–SEVERAL: investment, 201604 financing round Series C €25m led by new investor Gilde Healthcare 2016-04-11
United States (govt)–Evolva: biomaterials, –201604 collab CRADA to develop new materials for the US Navy 2016-04-11
Cunesoft–Bavaria (govt): investment, 201604 financing round Series A 7-digit €na incl returning co-investor Bayern Kapital 2016-04-07
Cunesoft–High-Tech Gründerfonds: investment, 201604 financing round Series A 7-digit €na incl returning co-investor HTGF 2016-04-07
Cunesoft–Occident Group: investment, 201604 financing round Series A 7-digit €na incl new + lead investor Occident Group AG 2016-04-07
Cunesoft–SEVERAL: investment, 201604 financing round Series A 7-digit €na led by Occident Group + incl HTGF + Bayern Kapital 2016-04-07
Qiagen–BioTeam: bioinformatics, 201604 collab existent to create high-performance appliance with CLC Genomics Server + BioTeam Appliance platform 2016-04-05
Qiagen–Intel: bioinformatics, 201604 collab existent to develop reference architecture for high-volume whole genome data analysis 2016-04-05
NEO New Oncology–Siemens: investment, 201603 acquisiton by Siemens Healthcare GmbH 2016-03-31
Almirall–Grünenthal: investment, 201603– acquisition 100% of Almirall de Mexico SA de CV by Grünenthal ANNNOUNCED 2016-03-15
Grünenthal–Axxam: drug discovery services, 201603– collab to discover small moleucule lead structures to treat pain + inflammation 2016-03-03
Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon 2016-02-18
Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA 2016-02-17
Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors 2016-02-17
Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition 2016-02-12
Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease 2016-02-02
Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund 2016-02-02
Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs 2016-01-11
Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders 2016-01-11
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix 2016-01-07
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG 2016-01-01
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems 2016-01-01
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program 2016-01-01
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets 2016-01-01
Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen 2015-12-31
Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen 2015-12-31
Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen 2015-12-31
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform 2015-12-22
Complix–Selexis: biological contract manufacturing, 201512– supply SUREtechnology platform to enable production of Alphabody candidate CMX-02 2015-12-14
Basilea–SEVERAL: credit, 201512 senior unsecured convertible bonds CHF200m with coupon of 2.75% per annum due 2022 2015-12-09
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd 2015-12-09
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint 2015-12-08
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare 2015-11-25
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors 2015-11-25
Merck (DE)–Univ Cape Town: malaria drug, 201511– collab research with UCT H3D to develop anti-malarial drug candidates using Merck compound library 2015-11-19
Greiner–Oncgnostics: cervical cancer test, 201511– distribution of GynTect test by Greiner Bio-One in DACH + FR + GB + Benelux 2015-11-18
Oncotest–Charles River: investment, 201511 acquisition of Oncotest GmbH for €34m in cash + €2m milestones 2015-11-18
Nestlé–ImaBiotech: mass spectrometry services, 201511– supply Multimaging services for Galderma’s drug development 2015-11-10
Syngenta–DSM: microbial agricultural solutions, 201511– collab developm microbial-based solutions incl bio-controls + bio-pesticides + bio-stimulants 2015-11-06
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m 2015-11-02
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund 2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m 2015-11-01
Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors 2015-10-30
GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015 2015-10-29
Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share 2015-10-27
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management 2015-10-21
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round 2015-10-09
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech 2015-10-01
JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate 2015-09-28
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform 2015-09-17
Evolva–SEVERAL: investment, 201509 rights offering CHF57.4m 2015-09-16
Nestlé–Lipid Therapeutics: gastrointestinal drug, 201609– license excl to develop + market LT-02 ww excl Europe + Australia to Nestlé Health Science 2015-09-16
Lophius–SEVERAL: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-10
Lophius–High-Tech Gründerfonds: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-09
Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A 2015-09-02
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis 2015-09-01
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management 2015-09-01
Hisun Pharmaceutical–IMD Natural Solutions: drug discovery, 201508– collab using IMD natural product lead discovery platform incl €4m investment 2015-08-31
IMD Natural Solutions–Hisun Pharmaceutical: investment, 201508 equity investment €4m as part of collab with Zhejiang Hisun Pharmaceutical Co Ltd 2015-08-31
Immatics–Texas (govt): grant, 201508 launch of Immatics US Inc supported by $19.7m grant from CPRIT 2015-08-26
Immatics–Univ Texas: cell therapy, 201508– collab launch joint venture Immatics US Inc with MD Anderson to advance adoptive cellular therapies 2015-08-26
Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund 2015-08-26
Nomad Bioscience–Denka: investment, 201508–201708 acquisition up to €75m of 51% share in Icon Genetics GmbH + after 2y acquiring rest by Denka 2015-08-07
Mereo BioPharma–Novartis: investment, 201507 Novartis receives equity stake in consideration for acquisition of 3 programmes from Novartis by Mereo 2015-07-29
Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors 2015-07-28
next pagenext page 1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top